Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Polycythemia Vera 5Thrombocythemia, Essential 3Primary Myelofibrosis 3Myeloproliferative Disorders 2Hodgkin Disease 2Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 193fludarabine phosphate 121Peripheral Blood Stem Cell Transplantation 106Etoposide 106Mycophenolic Acid 94Filgrastim 91Doxorubicin 85Whole-Body Irradiation 83Tacrolimus 80Melphalan 78Brentuximab Vedotin 77Busulfan 74Radiotherapy 73fludarabine 67Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 43pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hodgkin Disease × givinostat × Clear all
NCT00496431 2022-01-27

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Italfarmaco

Phase 1/2 Terminated
19 enrolled
Lymphoid

Hodgkin Disease

NCT00792467 2021-05-11

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Italfarmaco

Phase 1/2 Completed
24 enrolled 13 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡